President and Chief Executive Officer

Chief Patient Advocate Emerita

Transcript : Amicus Therapeutics, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 03

Amicus Therapeutics Announces the Presentation of New 4-Year Data for Pombiliti (Cipaglucosidase alfa-atga) + Opfolda®?

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda

Senior Director Key Opinion Leader Engagement & Marketing

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. The Senior Director of KOL Engagement is responsible for KOL identification, mapping, and strategies across Amicus’ therapeutic areas in the United States, ensuring alignment with the company’s clinical, medical affairs, and commercial objectives while maintaining scientific integrity and compliance.

Sign up with Google

Sign in with Google